Litcius/Paper detail

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

Xiaojun Feng, Yanan Wang, Wenxu Chen, Suowen Xu, Lingli Li, Yadi Geng, Aizong Shen, Hui Gao, Lei Zhang, Sheng Liu

2020Aging36 citationsDOIOpen Access PDF

Abstract

Sirtuin 3 (SIRT3) is a type III histone deacetylase that inhibits cardiac hypertrophy. It is mainly localized in the mitochondria and is thus implicated in mitochondrial metabolism. Recent studies have shown that SIRT3 can also accumulate in the nuclear under stressed conditions, and participated in histone deacetylation of target proteins. Poly [ADP-ribose] polymerase 1 (PARP-1) functions as an important PARP isoform that was involved in cardiac hypertrophy. Our experiments showed that SIRT3 accumulated in the nuclear of cardiomyocytes treated with isoproterenol or SIRT3 overexpression. Moreover, overexpression of SIRT3 by adenovirus inhibited the expression of cardiac hypertrophic genes-ANF and BNP, as well as abrogating PARP-1 activation induced by isoproterenol or phenylephrine. In addition, co-immunoprecipitation experiments revealed that SIRT3 could interact with PARP-1, and overexpression of SIRT3 could decrease the acetylation level of PARP-1. Our results indicate that SIRT3 exerts protective effects against cardiac hypertrophy by reducing the level of acetylation and activity of PARP-1, thus providing novel mechanistic insights into SIRT3-mediated cardiprotective actions.

Topics & Concepts

SIRT3SirtuinHistoneAcetylationPoly ADP ribose polymerasePARP inhibitorGene isoformHistone deacetylaseCell biologyMitochondrionChromatin immunoprecipitationChemistryMyocyteCancer researchBiologyEndocrinologyMolecular biologyGene expressionBiochemistryGenePolymerasePromoterPARP inhibition in cancer therapySirtuins and Resveratrol in MedicineToxin Mechanisms and Immunotoxins
SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity | Litcius